Innovating Works

ALACRIS

Desconocido
3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... ALACRIS THERANOSTICS GMBH participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado
iPC: individualizedPaediatricCure Cloud based virtual patient models for precision paediatric oncology ALACRIS THERANOSTICS GMBH participó en un H2020: H2020-SC1-DTH-2018-2020 Effective personalized medicine for paediatric cancers must address a multitude of challenges, including domain-specific challenges. To over...
2018-12-19 - 2023-11-30 | Financiado
TAPAS: TArgeting Platelet Adhesion receptors in thrombosiS ALACRIS THERANOSTICS GMBH participó en un H2020: H2020-MSCA-ITN-2017 TAPAS will position Europe at the forefront of innovative research to prevent thrombosis and thromboinflammation, and will train a uniquely-...
2017-08-17 - 2022-06-30 | Financiado
CanPathPro: Generation of the CanPath prototype a platform for predictive cancer pathway modeling ALACRIS THERANOSTICS GMBH tramitó un H2020: H2020-BIOTEC-2014-2015 Recent developments in omics technologies demand implementation of systems biology approaches to facilitate analysis and interpretation of t...
2016-02-25 - 2021-11-30 | Financiado
SMARTool: Simulation Modeling of coronary ARTery disease a tool for clinical decision support ALACRIS THERANOSTICS GMBH participó en un H2020: H2020-PHC-2014-2015 SMARTool aims at developing a platform based on cloud technology, for the management of patients with coronary artery disease (CAD) by stand...
2015-11-11 - 2019-06-30 | Financiado
PROSEQO: PROtein SEQuencing using Optical single molecule real time detection ALACRIS THERANOSTICS GMBH participó en un H2020: H2020-FETOPEN-2014-2015 The advent of analytical techniques with extremely low limits of detection has led to dramatic progresses mostly in the field of nucleic aci...
2015-11-03 - 2019-02-28 | Financiado
TREGeneration: Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoieti... ALACRIS THERANOSTICS GMBH participó en un H2020: H2020-PHC-2014-2015 Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg...
2014-12-01 - 2021-12-31 | Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... ALACRIS THERANOSTICS GMBH participó en un FP6: Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
2015-01-01 - 2019-12-31 | Financiado
ONCOTRACK: OncoTrack - Methods for systematic next generation oncology biomarker development ALACRIS THERANOSTICS GMBH participó en un FP6: We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients wit...
2011-01-01 - 2016-12-31 | Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... ALACRIS THERANOSTICS GMBH participó en un FP7: Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
Financiado
ONCOTRACK: OncoTrack Methods for systematic next generation oncology biomarker development ALACRIS THERANOSTICS GMBH participó en un FP7: We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients wit...
Financiado
ITFoM: IT Future of Medicine ALACRIS THERANOSTICS GMBH participó en un FP7: Data-rich, individualised medicine poses unprecedented challenges for IT, in hardware, storage and communication. We propose a data-driven,...
Financiado
SYBIL: Systems biology for the functional validation of genetic determinants of skeletal diseases ALACRIS THERANOSTICS GMBH participó en un FP7: "The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the a...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.